Loading
Stamford Pharmaceuticals injects a modified common-cold virus carrying an immune-signalling gene into skin cancers, and is testing it alongside a standard tablet for advanced basal cell carcinoma.
Stamford Pharmaceuticals, Inc., which moved its head office to Austin, Texas in 2023, is a clinical-stage oncology company developing gene therapies for skin and visceral cancers. SP-002 is an adenoviral vector (serotype 5) that delivers the gene for interferon gamma into the tumour. A phase 2 study tests SP-002 with the hedgehog pathway inhibitor vismodegib in locally advanced basal cell carcinoma (NCT06344052); the company plans a phase 2/3 study in high-risk nodular basal cell carcinoma in 2027 and has an open IND for cutaneous squamous cell carcinoma. Its SP-500 platform conjugates the vector with small-molecule payloads, with preclinical candidates for bladder, pancreatic, head and neck, prostate and breast cancer. Its first registered cancer trial, NCT06344052, was posted on ClinicalTrials.gov in April 2024; an earlier phase 2a study of SP-002 (NCT04416516) is registered under a different sponsor name.
Shares To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma, Basal cell carcinoma.
Shares To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma, Basal cell carcinoma.
Shares To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma, Basal cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/